Clinical trial · Observational
MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-center, observational study in patients with multiple myeloma, conducted both retrospectively and prospectively. The study aims to improve understanding of the biological and clinical factors that influence disease progression, relapse, and treatment resistance. The study will integrate clinical information with advanced genomic and molecular analyses, including whole genome and RNA sequencing, as well as circulating tumor markers, to identify features linked to therapy response and disease behavior. All data will be securely stored, maintaining patient confidentiality, to build a comprehensive map of multiple myeloma that may guide more personalized future treatments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloma Multiple | Multiple Myeloma | CURATED_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response assessment (according to IMWG criteria) and / or disease progression (PD)
- timeFrame
- 12 months after the start of therapy, in pre-neoplastic groups , only PD will be considered
Secondary outcomes (3)
- measure
- Response to treatment <VGPR (according to IMWG criteria) and/or disease progression (PD)
- timeFrame
- From baseline to disease progression (PD), assessed up to 24 months.
- measure
- Presence and/or absence of "secondary" tumor clone(s)
- timeFrame
- From baseline to disease progression (PD), assessed up to 24 months.
- measure
- Presence and/or absence of differences between baseline characteristics and progression features
- timeFrame
- From baseline to disease progression (PD), assessed up to 24 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18+ * Signed CI for study partecipation and personal data processing. * Diagnosis of monoclonal gammopathy, or of acrive multiple myaloma (NDMM/RMM/RRMM) Exclusion Criteria: * None
References
Publications (0)
Data not yet available